Sandoz Egypt Partners Up To Launch Rituximab Biosimilar

Projected Savings For NHL Estimated At 40%

 
• By Dean Rudge

Sandoz’ operation in Egypt has banded together with the Egyptian Cancer Society to introduce the firm’s biosimilar to Roche’s Rituxan/MabThera, three years after Hikma in-licensed a rituximab biosimilar from Celltrion.

Middle East
The launch 'represents a clear added value to the treatment of blood cancers in Egypt,' Sandoz says • Source: Shutterstock

More from Biosimilars

More from Products